Patrick Thompson, MD

University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States

Disclosure information not submitted.

Presentation(s):

• Paper 24 - A PHASE IB STUDY TO EVALUATE THE FEASIBILITY OF NIVOLUMAB OR NIVOLUMAB WITH AZACITIDINE IN PATIENTS WITH RECURRENT, RESECTABLE OSTEOSARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION

  Thursday, November 14, 2024
  1:45 PM – 3:15 PM PST